Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for approximately 30% of all cases. While the standard treatment for DLBCL is chemotherapy, a significant number of patients experience relapse or have refractory disease, meaning that the cancer does not respond to initial treatment. In such cases, allogeneic hematopoietic stem-cell transplantation (allo-HSCT) has emerged as a potential therapeutic option.
Allo-HSCT involves the transfer of healthy stem cells from a donor to a recipient, with the goal of replacing the recipient’s diseased or damaged cells with healthy ones. In the case of DLBCL, allo-HSCT offers several potential benefits. Firstly, it allows for the use of higher doses of chemotherapy or radiation therapy, which can be more effective in eliminating cancer cells. Secondly, it provides a new immune system that can recognize and attack cancer cells, known as the graft-versus-lymphoma effect. Lastly, allo-HSCT can be used as a consolidation therapy after achieving remission with chemotherapy, reducing the risk of relapse.
Several scientific reports have shed light on the role of allo-HSCT in treating relapsed/refractory DLBCL. A study published in the Journal of Clinical Oncology in 2013 evaluated the outcomes of 397 patients who underwent allo-HSCT for relapsed/refractory DLBCL. The study found that allo-HSCT resulted in a 5-year overall survival rate of 47%, with a relapse rate of 35%. Importantly, patients who achieved complete remission before transplantation had significantly better outcomes compared to those with residual disease.
Another study published in Blood in 2016 investigated the impact of pre-transplantation positron emission tomography (PET) scans on the outcomes of allo-HSCT in DLBCL patients. The study included 241 patients and found that a negative PET scan before transplantation was associated with a significantly higher 3-year progression-free survival rate compared to a positive PET scan (61% vs. 38%). This suggests that PET scans can help identify patients who are more likely to benefit from allo-HSCT.
Despite these promising findings, allo-HSCT is not without risks. The procedure carries a risk of complications, including graft-versus-host disease (GVHD), where the donor’s immune cells attack the recipient’s tissues. GVHD can affect various organs and can be life-threatening. In addition, allo-HSCT requires finding a suitable donor, which can be challenging, especially for patients from ethnic minority backgrounds.
To address these challenges, ongoing research is focused on improving patient selection criteria, optimizing conditioning regimens (chemotherapy or radiation therapy given before transplantation), and developing strategies to prevent and manage complications such as GVHD. Additionally, the use of targeted therapies and immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, in combination with allo-HSCT is being explored to enhance treatment outcomes.
In conclusion, allo-HSCT plays a crucial role in the management of relapsed/refractory DLBCL. Scientific reports have demonstrated its potential to improve survival rates and reduce the risk of relapse. However, careful patient selection and close monitoring for complications are essential. Ongoing research aims to further refine the use of allo-HSCT in DLBCL and explore novel treatment approaches to enhance its efficacy.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/the-salvage-role-of-allogeneic-hematopoietic-stem-cell-transplantation-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-scientific-reports/